Skip to main content
. Author manuscript; available in PMC: 2022 Jan 27.
Published in final edited form as: Clin Cancer Res. 2020 Jun 29;26(15):3928–3935. doi: 10.1158/1078-0432.CCR-20-0953

Figure 2.

Figure 2.

Updated progression-free survival analyses continue to support the addition of trastuzumab to the treatment of advanced/recurrent uterine serous carcinoma (USC). Left: Median PFS was 8.0 months in patients who received CP and 12.9 months in patients who received CP+T (HR 0.46, 90% CI 0.28–0.76, p=0.005). Benefit from the addition of trastuzumab was greatest in those undergoing primary treatment. Right, top: Median PFS was 9.3 (CP) versus 17.7 (CP+T) months among 41 stage III-IV pts undergoing primary treatment (HR 0.44, 90%CI 0.23–0.83, p=0.015). Right, bottom: Median PFS 7.0 (CP) versus 9.2 (CP+T) months among 17 patients with recurrent disease (HR 0.12, 90%CI 0.03–0.48, p=0.004)